

Search

EN

%{var0} (02268.HK) Stock Price, Chart, News and AI analysis | Edgen

Back

02268.HK

%{var0} (02268.HK) Price

02268.HK Stock Price Chart

undefined Price

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

--

Open

--

Day's Range

-

52 week range

-

Volume

--

Avg.Volume

--

EPS (TTM)

--

Dividend yield

--

Market Cap

--

Features

AI Copilot for Stock & Crypto

Price Prediction

Fundraise Tracker

Market Sentiment

Technical Analysis

Crypto Comparison

Trading Strategies

Megabrain Investors Picks

Trading Mindshare

Technical Signals

Resources

Market

Terms of Use Privacy Policy Sitemap

© 2025 Finture Development Limited. All rights reserved

No data

No Data Yet

Supported by

1D

--

5D

--

30D

--

6M

--

YTD

--

1Y

--

1D

--

5D

--

30D

--

6M

--

YTD

--

1Y

--

Related News

BOCOM Lifts WuXi XDC Target to HK$91 on TOT BIOPHARM Buyout

Jan 20 2026, 02:24

BOCOM Lifts WuXi XDC Target to HK$91 on TOT BIOPHARM Buyout

WuXi XDC received a HK$91 price target from BOCOM International after announcing a tender offer to acquire at least 60% of TOT BIOPHARM for up to HK$3.1 billion.

WuXi XDC Bids HK$2.79 Billion for TOT BIOPHARM at 60% Premium

Jan 14 2026, 17:38

WuXi XDC Bids HK$2.79 Billion for TOT BIOPHARM at 60% Premium

WuXi XDC (02268.HK) announced a voluntary general offer to acquire TOT BIOPHARM (01875.HK) for HK$4 per share, representing a 60% premium over its last closing price.

WuXi XDC Projects Over 45% Revenue Growth for FY2025

Jan 14 2026, 17:28

WuXi XDC Projects Over 45% Revenue Growth for FY2025

Biotech manufacturer WuXi XDC issued strong forward guidance, forecasting year-on-year revenue growth to exceed 45% for its 2025 fiscal year.